Biomind Labs Inc.
BMND
CNSX
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 609.62% | -29.03% | 765.05% | -13.78% | -12.98% |
| Depreciation & Amortization | -- | -- | -100.00% | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 609.62% | -30.38% | 484.64% | -4.29% | -14.75% |
| Operating Income | -609.62% | 30.38% | -484.64% | 4.29% | 14.75% |
| Income Before Tax | -485.84% | -55.84% | -427.51% | -197.97% | 45.07% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -485.84% | -55.84% | -427.51% | -197.97% | 45.07% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -485.84% | -55.84% | -427.51% | -197.97% | 45.07% |
| EBIT | -609.62% | 30.38% | -484.64% | 4.29% | 14.75% |
| EBITDA | -608.97% | 29.47% | -498.59% | 1.81% | 12.98% |
| EPS Basic | -486.67% | -44.44% | -431.82% | -160.00% | 46.43% |
| Normalized Basic EPS | -511.11% | 27.27% | -421.43% | -166.67% | 50.00% |
| EPS Diluted | -486.67% | -44.44% | -431.82% | -160.00% | 46.43% |
| Normalized Diluted EPS | -511.11% | 27.27% | -421.43% | -166.67% | 50.00% |
| Average Basic Shares Outstanding | 0.00% | 0.00% | 0.00% | 4.16% | 3.76% |
| Average Diluted Shares Outstanding | 0.00% | 0.00% | 0.00% | 4.16% | 3.76% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |